納豆激酶 Nattokinase × 末梢循環
The evidence base for nattokinase improving peripheral circulation is too thin and too indirect to support any graded conclusion.
The evidence base for nattokinase improving peripheral circulation is too thin and too indirect to support any graded conclusion. The only human trial that directly touches peripheral microcirculation is a 9-subject, single-dose, industry-funded crossover study using skin-temperature recovery as a surrogate, with no numeric effect size; a second 12-subject crossover trial shows only transient, within-normal-range fibrinolysis-marker shifts (D-dimer, FDP), which is a plausible mechanism rather than a demonstrated circulation benefit. The single trial with a clinical endpoint, LONFLIT-FLITE, prevented flight-associated DVT but used a pycnogenol + nattokinase COMBINATION product (Flite Tabs / pinokinase), so its effect cannot be attributed to nattokinase alone. There is no meta-analysis, no large RCT with peripheral circulation as a primary endpoint, no Examine coverage of this condition (found_in_examine=false), and no endorsement from the AHA, the Society for Vascular Surgery, Mayo, Cleveland Clinic, or Harvard. Given a coverage gap plus a real bleeding-risk signal from the fibrinolytic/antiplatelet mechanism, the honest grade is Undetermined (U).
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.432
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群多把納豆激酶以「納豆紅麴」複方形式討論，主軸是三高/心血管保養，末梢循環（手腳冰冷）多為附帶心得而非主訴；PTT regimen 板少數使用者反映冬天手腳較不冰冷、戴婚戒變鬆，屬個人正面經驗但樣本少。Mobile01 則出現強烈安全示警，提醒納豆激酶有纖溶/抗凝血作用、與抗凝血藥併用恐內出血、且不可取代正規用藥。整體反應分歧、缺乏針對末梢循環的社群共識。
分歧 / 無共識（少數 PTT 使用者回報冬天手腳較不冰冷的正面複方心得，但末梢循環非社群主要討論用途，且 Mobile01 偏重出血風險示警）
- 出血風險升高（與 Warfarin/Eliquis/Xarelto 等抗凝血藥併用，Mobile01 多人示警，嚴重恐內出血）
- 腸胃敏感者空腹服用易不適（建議飯後）
- 與葡萄柚/柚子的交互作用疑慮（多因複方含紅麴而提醒）
依論壇被提及頻率，非銷售或品質排序。
- 威德 Wedar 薇達納豆紅麴（好市多/官網通路，社群常提 CP 值高）
- 大研生醫納豆紅麴
- PowerHero 勁漢英雄
- 社群多以「納豆紅麴」複方品牌為主，少有純末梢循環訴求的單方品牌
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 監督式運動治療（規律步行訓練）
- 戒菸與心血管危險因子控制
- Cilostazol
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-peripheral-circulation-INT-nattokinase-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "納豆激酶能改善末梢循環",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}